Company
Atsena Therapeutics
Focused on bringing the life-changing power of genetic medicine – to reverse or prevent blindness
Also known as Atsena, Atsena Therapeutics Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Atsena Therapeutics Inc.
- atsenatx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
ATSENA THERAPEUTICS is a clinical-stage gene therapy company developing first- and best-in-class treatments for inherited retinal diseases — conditions that cause progressive, irreversible vision loss and for which few or no approved therapies exist.
Funding snapshot
- Total raised
- $150MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series C, $150M2025-04-02
Funding rounds
- Series C
- $150M2025-04-02, Company stated
- Round, 2025
- $90M2025-03-27, SEC form D sold, 14 investors
- Round, 2023
- $24.5M2023-08-28, SEC form D sold, 10 investors
- Round, 2020
- $27.5M2020-12-15, SEC form D sold, 11 investors
- Round, 2020
- $4.1M2020-04-24, SEC form D sold, 7 investors
Products
- Other
- ATSN-101
- Web
- ATSN-101
- Other
- ATSN-201
- Web
- ATSN-201
- Other
- ATSN-301
- Web
- ATSN-301
- Other
- ATSN-401
- Web
- ATSN-401
Loading relationship preview